Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Inclusion Criteria: The subjects are not limited by gender, age from 18 to 75 years old; Histopathologically confirmed squamous cell carcinoma of the head and neck cancer; Locally advanced squamous cell carcinoma diagnosed as T3-4 or N+ stage according to AJCC 8th edition staging; ECOG score 0-1; without distant metastasis; received induction chemotherapy plus immunotherapy, followed by surgery The expected survival is expected to be no less than 6 months. No contraindications to chemotherapy, immunotherapy, and radiotherapy; Exclusion Criteria: Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ) Received any systemic anti-tumor therapy for target lesions before induction chemotherapy and immunotherapy; Previously experienced head and neck radiation therapy; Subjects who have used corticosteroids (>10 mg/day prednisone or other equivalent hormones) or other immunosuppressive agents for systemic treatment within 1 month before enrollment. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy at therapeutic doses of prednisone ≤10 mg/day are permitted; Patients with pleural effusion, pericardial effusion or ascites that need to be drained with clinical symptoms, or who have received serous cavity effusion drainage for the purpose of treatment within 2 weeks before enrollment; Severe comorbidities including myocardial infarction, arrhythmia, cerebral vascular disease, ulceration disease, mental disease and uncontrolled diabetes